EPHA2 and breast cancer: Furthermore, EPHA2 overexpression in HER2+ BC cells has been demonstrated to confer innate resistance to trastuzumab, indicating that it could be used as a drug target or prognostic marker for patients with trastuzumab-resistant HER2+ BC (39, 40).